Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Stretches ZzzQuil Sleep Brand Into Supplement Space With PureZzzs

Executive Summary

P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G hopes to reach $4.5bn in e-commerce sales in 2018, up from $3bn in 2017.

You may also be interested in...



VapoCool Adds Menthol To P&G's DayQuil, NyQuil Cough/Cold Remedies

Liquid and caplet DayQuil and NyQuil Severe with VapoCool, also offered in cold/flu formulations, are on retailer shelves ready for the cold season. P&G also increases amount of menthol in its Vicks Severe Medicated Drops sore throat lozenges to mark 125th anniversary Vicks line introduction.

VapoCool Adds Menthol To P&G's DayQuil, NyQuil Cough/Cold Remedies

Liquid and caplet DayQuil and NyQuil Severe with VapoCool, also offered in cold/flu formulations, are on retailer shelves ready for the cold season. P&G also increases amount of menthol in its Vicks Severe Medicated Drops sore throat lozenges to mark 125th anniversary Vicks line introduction.

P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

P&G’s planned purchase of Merck KGaA’s consumer health care business will grow its personal health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor framed the acquisition as another step in the firm's ongoing portfolio shakeup.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel